Dopamine D1 receptor antagonist reduces stimulant-induced conditioned place preferences and dopamine receptor supersensitivity.


Journal

Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264

Informations de publication

Date de publication:
01 2020
Historique:
received: 23 01 2019
accepted: 12 07 2019
pubmed: 3 8 2019
medline: 1 1 2021
entrez: 3 8 2019
Statut: ppublish

Résumé

Repeated administration of stimulants induces conditioned place preference (CPP). Dopamine receptor supersensitivity is developed in stimulant-induced CPP animals; however, dopamine receptor subtypes associated with the development of supersensitivity in CPP animals are largely unknown. The present preclinical study aimed to examine whether dopamine D1 or D2 receptor antagonists exert inhibitory effects on stimulant-induced psychological behaviors. Additionally, the authors aimed to elucidate the role of dopamine receptor supersensitivity on the development of reward-related behavior. Sprague Dawley rats subjected to methamphetamine- and cocaine-induced CPP tests were treated with dopamine D1 (SCH23390) or D2 (sulpiride) receptor antagonists. Following the CPP experiment, rats were challenged with apomorphine (dopamine receptor agonist), and locomotor activity was measured. Methamphetamine- and cocaine-induced CPP was reduced with the administration of SCH23390, but not sulpiride. In addition, the apomorphine challenge evoked an increase in locomotor activity in stimulant-pre-treated rats, reflecting dopamine receptor supersensitivity. SCH23390 pre-treatment inhibited the development of dopamine receptor supersensitivity, while sulpiride demonstrated no inhibitory effects. These results suggest that the dopamine D1 receptor antagonist SCH23390 inhibits the development of dopamine receptor supersensitivity which is associated with the development of CPP.

Identifiants

pubmed: 31372696
doi: 10.1007/s00210-019-01694-3
pii: 10.1007/s00210-019-01694-3
doi:

Substances chimiques

Benzazepines 0
Central Nervous System Stimulants 0
DRD2 protein, rat 0
Dopamine Antagonists 0
Drd1 protein, rat 0
Receptors, Dopamine D1 0
Receptors, Dopamine D2 0
SCH 23390 0
Methamphetamine 44RAL3456C
Sulpiride 7MNE9M8287
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-138

Commentaires et corrections

Type : ErratumIn

Références

Eur Neuropsychopharmacol. 2008 Aug;18(8):551-6
pubmed: 18284941
Pharmacol Biochem Behav. 2011 May;98(3):449-54
pubmed: 21334368
Behav Brain Res. 1999 Aug;103(1):55-61
pubmed: 10475164
PLoS One. 2013 Nov 04;8(11):e78258
pubmed: 24223783
Pharmacol Biochem Behav. 1995 Jan;50(1):23-7
pubmed: 7700950
Brain Res Bull. 1996;40(3):201-7
pubmed: 8736582
J Ethnopharmacol. 1998 Feb;60(1):33-42
pubmed: 9533430
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
pubmed: 8401595
J Pharmacol Exp Ther. 1994 Jul;270(1):209-18
pubmed: 8035317
Pharmacol Biochem Behav. 1996 Sep;55(1):11-7
pubmed: 8870032
Int J Neurosci. 2010 Nov;120(11):691-7
pubmed: 20942582
Pharmacol Biochem Behav. 1991 Jun;39(2):465-8
pubmed: 1682950
J Ethnopharmacol. 1999 Jul;66(1):25-31
pubmed: 10432204
Biol Psychiatry. 2014 Jul 1;76(1):2-3
pubmed: 24925888
Nat Neurosci. 2013 May;16(5):632-8
pubmed: 23542690
Eur J Neurosci. 2009 Apr;29(8):1641-53
pubmed: 19419427
Acta Pharmacol Sin. 2016 Feb;37(2):157-65
pubmed: 26687935
Neurosci Biobehav Rev. 2018 Jun;89:13-28
pubmed: 29577963
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3513-8
pubmed: 15716360
J Pharmacol Exp Ther. 2007 Nov;323(2):599-605
pubmed: 17675585
Eur J Pharmacol. 2014 Nov 15;743:126-32
pubmed: 25261038
Synapse. 1998 Oct;30(2):181-93
pubmed: 9723788
Pharmacol Res. 2001 Dec;44(6):473-9
pubmed: 11735353
Chin J Physiol. 1998 Jun 30;41(2):85-92
pubmed: 9801838
Pharmacol Biochem Behav. 1999 Jul;63(3):407-12
pubmed: 10418781
Pharmacol Biochem Behav. 1995 Dec;52(4):759-63
pubmed: 8587917
J Pharmacol Exp Ther. 2009 Aug;330(2):633-40
pubmed: 19448141
Am Psychol. 2016 Nov;71(8):670-679
pubmed: 27977239
Psychopharmacology (Berl). 2007 Apr;191(3):719-30
pubmed: 16835769
Psychopharmacology (Berl). 2005 Jun;180(1):21-32
pubmed: 15682301
Psychopharmacology (Berl). 2016 Mar;233(5):893-903
pubmed: 26650612
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:9-16
pubmed: 23793001
Neuropsychopharmacology. 2001 Feb;24(2):97-129
pubmed: 11120394
Mol Neurobiol. 2015 Dec;52(3):1152-1164
pubmed: 25307288
Behav Pharmacol. 2001 Dec;12(8):603-11
pubmed: 11856897
Postgrad Med. 2009 Nov;121(6):176-96
pubmed: 19940429

Auteurs

Sun Mi Gu (SM)

College of Pharmacy and Medical Research Center, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk, 28160, Republic of Korea.

Hye Jin Cha (HJ)

National Institute of Food and Drug Safety Evaluation, 187, Osongsaengmyeong 2-ro, Heungdeok-gu, Cheongju, Chungbuk, 28159, Republic of Korea.

So Woon Seo (SW)

College of Pharmacy and Medical Research Center, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk, 28160, Republic of Korea.

Jin Tae Hong (JT)

College of Pharmacy and Medical Research Center, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk, 28160, Republic of Korea. jinthong@chungbuk.ac.kr.

Jaesuk Yun (J)

College of Pharmacy and Medical Research Center, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk, 28160, Republic of Korea. jyun@chungbuk.ac.kr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH